The Congressional Budget Office this week released a report that examines the different components of what putting together a single-payer system could involve, as well as the implications. Here we highlight 2 sections of the report that are likely of interest to those following biosimilars, drug pricing and healthcare cost containment.
Rather than release a hard set of numbers, the Congressional Budget Office (CBO) released a report this week about key policy considerations policymakers must think about if a single-payer system, such as Medicare for All, is created.
Unlike other CBO reports, it is not so much a financial analysis of the impact on the federal budget or deficits, but rather looks at different components of what putting together such a system could involve, as well as the implications. Here we highlight 2 sections of the report that are likely of interest to those following biosimilars.
Prescription Drug Pricing
The CBO said the impact of a single-payer system on pharmaceutical manufacturers is uncertain. While prescription drug products are sold globally, the United States is the largest single market and also has the highest drug prices. On the one hand, if average prescription drug prices fell under a single-payer system in the United States, manufacturers might be able to counter at least some of those declines if they could convince health systems in other countries to raise their prices.
If that doesn’t work, they might reduce research and development, the CBO said.
One possible outcome: if a single-payer system paid for a new drug on the basis of its additional benefit relative to existing drugs, manufacturers might refocus their research and development on drugs that provide significant additional benefits instead of drugs that provide marginal improvements over other existing drugs.
Payment rates under a single-payer system would affect manufacturers differently depending on their current payer mix.
After accounting for rebates and discounts, the average price per prescription for 50 top-selling brand-name specialty drugs was nearly twice as high in Medicare Part D as in Medicaid, CBO has said.
If a new system used an average of fee-for-service (FFS), Medicaid, and Medicare Part D prescription drug prices, the average price would fall for drugs under commercial insurance, but might increase for some Medicaid beneficiaries and those receiving veterans benefits.
Paying for Drugs
A single-payer system could affect the profits of drug manufacturers, which could affect their incentives to develop new drugs, the CBO said. A single-payer system could use several different methods to pay for prescription drugs, including value-based pricing, reference pricing, negotiated pricing, and administered pricing.
However, it could also use different payment methods for different types of drugs, such as by exempting certain types from the usual mechanism. In addition, some drugs could be placed on a nonpreferred drug list (as payers do currently).
Cost Containment
The cost of a single-payer system would depend the services covered, cost-sharing requirements, and provider payment rates, among other things. In addition to those design decisions, policymakers could use 2 other techniques to contain the growth of government spending on the single-payer plan and total healthcare spending: global budgets and utilization management.
Global budgets, which are commonly used in other nations, are rarely used as cost-control tools in the United States. They are difficult to implement in multipayer systems, with one exception being Maryland, which has a global budget for hospital spending, the CBO noted.
A single-payer system could also use utilization management, including care coordination and utilization review. The administrator of the single-payer plan could enforce utilization patterns by monitoring claims and identifying outliers. This is not a foreign concept to many people enrolled in private insurance, Medicare Advantage, or Medicare Part B plans, but would be a change for those enrolled in traditional Medicare FFS, the CBO noted.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.